We refined heterogeneous factors predicting clinical outcome in t(8;21) AML patients under induction with different cytarabine intensities.The specific KIT‐D816 (rather than general KITmut) is more associated with response, EFS, and OS under standard‐dose Ara‐C induction, and induction chemotherapy containing intermediate‐dose Ara‐C abrogates response disadvantage caused by KIT‐D816.Combination of CD19 and KIT can deliver a more explicit risk stratification profile and elaborately guide an individually risk‐adapted treatment strategy in t(8;21) AML. This evidence concerns the gene KIT and acute myeloid leukemia.